A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514585-39-00

Acronym

BHV4157-303

Enrollment

100

Registered

2024-07-30

Start date

2021-07-12

Completion date

2025-01-11

Last updated

2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder

Brief summary

Improvement in obsessive-compulsive symptomatology is assessed using the Y-BOCS change from baseline in the total score.

Detailed description

The change from baseline on the SDS total score and the CGI Severity score.

Interventions

DRUGTroriluzole

DRUGPlacebo for BHV-4157 capsules

DRUG100mg

DRUG140mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Improvement in obsessive-compulsive symptomatology is assessed using the Y-BOCS change from baseline in the total score.	—

Secondary

Measure	Time frame
The change from baseline on the SDS total score and the CGI Severity score.	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026